SPOTLIGHT -
September 11th 2025
More than 20 years later, what have we learned about PTSD, resiliency, and trauma?
September 5th 2025
August 13th 2025
Hurricane Katrina's legacy highlights the urgent need for trauma-informed mental health care in disaster recovery, addressing PTSD and long-term emotional impacts.
July 23rd 2025
Stay informed on PTSD treatment insights, including complex PTSD recognition, diagnostic nuances, and the link between migraines and trauma.
July 18th 2025
The FDA advisory committee votes against brexpiprazole plus sertraline for PTSD, citing insufficient efficacy despite some positive trial results.
Stress and Anxiety Disorders Research Roundup: May 10, 2024
What is new in research on stress and anxiety disorders?
Read More
PTSD Research Roundup: April 26, 2024
What is new in research on posttraumatic stress disorder?
Brexpiprazole + Sertraline Combination for PTSD Submitted for sNDA Review
A supplemental new drug application was submitted for the combination of brexpiprazole and sertraline in the treatment of PTSD in adults.
MDMA-Assisted Therapy Shows Significant Positive Response on Self-Experience in Patients With PTSD
Lykos Therapeutics recently received priority review of MDMA-assisted therapy for patients with PTSD. Check out the latest research update here!
Bipolar Disorder Research Roundup: March 29, 2024
What is new in research on bipolar disorder?
5 Processes for Focus and Empowerment in Patients With PTSD
These 5 processes provide a focus for patients with PTSD...
The Week in Review: March 4-8
From an update on Prism for PTSD to the efficacy of home-use transcranial direct current stimulation for MDD, here are highlights from the week in Psychiatric Times.
Study Highlights Efficacy of Prism for PTSD in Alleviating Chronic PTSD Symptoms
The therapy is the first self-neuromodulation device for PTSD approved by the US Food and Drug Administration.
Psychiatry in the News: February 2024
Here are some updates from the world of psychiatry throughout the month of February.
The Week in Review: February 12-16
From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.
FDA Accepts, Grants Priority Review of NDA for MDMA-Assisted Therapy for PTSD
The treatment's PDUFA date is set for August 11, 2024.
Medication Pipeline: Antidepressants and ADHD Rx
Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.
Psychiatry in the News: January 2024
Here are some updates from the world of psychiatry throughout the month of January.
From the Pages of Psychiatric Times: January 2024
The experts weighed in on a wide variety of psychiatric issues for the January 2024 issue of Psychiatric Times.
The Week in Review: January 8-12
From substance use disorders in physicians to new research on the efficacy of MDMA-assisted therapy for PTSD, here are highlights from the week in Psychiatric Times.
Medication-Assisted Psychotherapy: The Past and Future of Psychiatry
Medication Pipeline: Schizophrenia and PTSD
Here's an update on which medications are on the horizon for the treatment of schizophrenia and PTSD.
Resolution #4: Improving the Treatment of Trauma in Israel, Gaza, and Elsewhere
What can we learn from war trauma?
Landmark Study Highlights Efficacy of MDMA-Assisted Therapy for PTSD
In a first of its kind study, MDMA-assisted therapy successfully supported patients with PTSD.
Processes and Interventions That Drive Improvement in PTSD
Here are 5 processes to provide focus and empowerment for patients with PTSD.
The Week in Review: January 1-5
From a groundbreaking new launch for PTSD in the United States to connections between antidepressant treatment and metabolic syndrome, here are highlights from the week in Psychiatric Times.
PTSD Research Roundup: January 5, 2024
First FDA-Approved Self-Neuromodulation Device for PTSD Officially Launches in the US
The device is now available at 2 US clinics, with training and installation currently underway at several other locations.
Psychiatry in the News: December 2023
Here are some updates from the world of psychiatry throughout the month of December.
Preliminary Phase 2 Data Shows Psilocybin for PTSD Is Well-Tolerated
Initial data from phase 2 safety profile for psilocybin in the treatment of PTSD indicates the treatment is well-tolerated.
NDA Submitted for MDMA-Assisted Therapy for Posttraumatic Stress Disorder
MAPS has submitted an NDA for MDMA-assisted therapy for patients with posttraumatic stress disorder.
Psychedelics Research Roundup: November 17, 2023
What is new in research on psychedelics?
From the Pages of Psychiatric Times: October 2023
The experts weighed in on a wide variety of psychiatric issues for the October 2023 issue of Psychiatric Times.
The Week in Review: October 16-20
From long-acting injectable antipsychotics for managing schizophrenia to mental health responses to the recent conflict in Israel, here are highlights from the week in Psychiatric Times.
Concurrent Treatment of Eating Disorders and PTSD Leads to Long-Term Recovery
Concurrent treatments targeting eating disorders and PTSD are needed to help these patients with complex conditions.